Skip to main content
SpringerLink
Log in

The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation?

Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

This review is not intended to cover in detail all aspects of the discovery and evolution of our understanding of the “alternative pathway” of complement activation, there are many excellent reviews that do this (see Fearon (CRC Crit Rev Immunol 1:1–32, 1979), Pangburn and Müller-Eberhard (Springer Semin Immunopathol 7:163–192, 1984)), but instead to give sufficient background for current concepts to be put in context. The prevailing textbook view, of components having a primary role as an alternative “pathway” for C3 activation, is challenged, with an argument developed for the primary role of the system being that of providing a surface-dependent amplification loop for both C3 and C5 activation. Whatever the mechanism by which the initial C3b molecule is generated, deposition onto a surface has the potential to target that surface for elimination. Elimination or escape from initial targeting is determined by a sophisticated and highly regulated amplification loop for C3 activation. This viewpoint of the system is then briefly developed to provide a context for therapeutic treatment of disease caused, at least in part, by dysregulated amplification of C3 activation, and to highlight some of the challenges that such therapies will face and need to address.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279–285

    Article  CAS  PubMed  Google Scholar 

  2. Kemper C1, Pangburn MK2, Fishelson Z (2014) Complement nomenclature 2014. Mol Immunol 61:56–58. https://doi.org/10.1016/j.molimm.2014.07.004

    Article  CAS  PubMed  Google Scholar 

  3. Nelson RA Jr (1958) An alternative mechanism for the properdin system. J Exp Med 108:515–535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pensky J, Hinz CF Jr, Todd EW, Wedgwood RJ, Boyer JT, Lepow IH (1968) Properties of highly purified human properdin. J Immunol 100:142–158

    CAS  Google Scholar 

  5. Götze O, Müller-Eberhard HJ (1974) The role of properdin in the alternate pathway of complement activation. J Exp Med 139:44–57

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chapitis J, Lepow IH (1976) Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. J Exp Med 143:241–257

    Article  CAS  PubMed  Google Scholar 

  7. Müller-Eberhard HJ, Nilsson U, Aronsson T (1960) Isolation and characterization of two beta1-glycoproteins of human serum. J Exp Med 111:201–215

    Article  PubMed  PubMed Central  Google Scholar 

  8. Blum L, Pillemer L, Lepow IH (1959) The properdin system and immunity. XIII. Assay and properties of a heat-labile serum factor (factor B) in the properdin system. Z Immun exp ther 118:349–357

    CAS  PubMed  Google Scholar 

  9. Götze O1, Müller-Eberhard HJ (1971) The c3-activator system: an alternate pathway of complement activation. J Exp Med 134:90–108

    PubMed  PubMed Central  Google Scholar 

  10. Alper CA, Goodkofsky I, Lepow IH (1973) The relationship of glycine-rich glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of human serum. J Exp Med 137:424–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pangburn MK, Müller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235:723–730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cooper NR (1973) Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med 137:451–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fearon DT, Austen KF, Ruddy S (1974) Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med 139:355–366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fearon DT, Austen KF, Ruddy S (1974) Properdin factor D. II. Activation to D by properdin. J Exp Med 140:426–436

  15. SV1 N, Carson M, el-Kabbani O, Kilpatrick JM, Moore D, Chen X, Bugg CE, Volanakis JE, DeLucas LJ (1994) Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol 235:695–708

  16. Lesavre PH, Müller-Eberhard HJ (1978) Mechanism of action of factor D of the alternative complement pathway. J Exp Med 148:1498–1509

    Article  CAS  PubMed  Google Scholar 

  17. Ballow M, Cochrane CG (1969) Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol 103:944–952

    CAS  PubMed  Google Scholar 

  18. Cochrane CG, Müller-Eberhard HJ, Aikin BS (1970) Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 105:55–69

    CAS  PubMed  Google Scholar 

  19. Vallota EH, Forristal J, Spitzer RE, Davis NC, West CD (1970) Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum. J Exp Med 131:1306–1324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vallota EH, Götze O, Spiegelberg HL, Forristal J, West CD, Müller-Eberhard HJ (1974) A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med 139:1249–1261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116:1–7

    CAS  PubMed  Google Scholar 

  22. Davis AE 3rd, Ziegler JB, Gelfand EW, Rosen FS, Alper CA (1977) Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A 74:3980–3983

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Daha MR, Van Es LA (1981) Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor. Immunology 43:33–38

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Müller-Eberhard HJ, Götze O (1972) C3 proactivator convertase and its mode of action. J Exp Med 135:1003–1008

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lachmann PJ, Nicol P (1973) Reaction mechanism of the alternative pathway of complement fixation. Lancet 1(7801):465–467

    Article  CAS  PubMed  Google Scholar 

  26. Abramson N, Alper CA, Lachmann PJ, Rosen FS, Jandl JH (1971) Deficiency of C3 inactivator in man. J Immunol 107:19–27

    CAS  PubMed  Google Scholar 

  27. Lachmann PJ, Müller-Eberhard HJ (1968) The demonstration in human serum of “conglutinogen-activating factor” and its effect on the third component of complement. J Immunol 100:691–698

    CAS  PubMed  Google Scholar 

  28. Ruddy S, Austen KF (1969) C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol 102:533–543

    CAS  PubMed  Google Scholar 

  29. Ekdahl KN1, Nilsson B (1995) Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b. J Immunol 154:6502–6510

    CAS  PubMed  Google Scholar 

  30. Whaley K, Ruddy S (1976) Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science 193:1011–1013

    Article  CAS  PubMed  Google Scholar 

  31. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 73:3268–3272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 146:257–270

    Article  CAS  PubMed  Google Scholar 

  33. Harrison RA, Lachmann PJ (1980) The physiological breakdown of the third component of human complement. Mol Immunol 17:9–20

    Article  CAS  PubMed  Google Scholar 

  34. Medicus RG, Schreiber RD, Götze O, Müller-Eberhard HJ (1976) A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A 73:612–616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Spitzer RE, Stitzel AE, Urmson J (1976) Interaction of properdin convertase and properdin in the alternative pathway of complement activation. Immunochemistry 13:15–20

    Article  CAS  PubMed  Google Scholar 

  36. Lachmann PJ, Halbwachs L (1975) The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 21:109–114

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Bokisch VA, Müller-Eberhard HJ, Cochrane CG (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129:1109–1130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Johnson U, Ohlsson K, Olsson I (1976) Effects of granulocyte neutral proteases on complement components. Scand J Immunol 5:421–426

    Article  CAS  PubMed  Google Scholar 

  39. Kirschfink M, Borsos T (1988) Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes. Mol Immunol 25:505–512

    Article  CAS  PubMed  Google Scholar 

  40. Matsushita M1, Fujita T (1995) Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology 194:443–448

    Article  CAS  PubMed  Google Scholar 

  41. Law SK, Minich TM, Levine RP (1984) Covalent binding efficiency of the third and fourth complement proteins in relation to pH, nucleophilicity, and availability of hydroxyl groups. Biochemistry 23:3267–3272

    Article  CAS  PubMed  Google Scholar 

  42. Fearon DT, Austen KF (1977) Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A 74:1683–1687

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bokisch VA, Dierich MP, Müller-Eberhard HJ (1975) Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A 72:1989–1993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Mardiney MR Jr, Müller-Eberhard HJ, Feldman JD. (1968) Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. Am J Pathol 53:253–261.

  45. Vogt W, Schmidt G, Von Buttlar B, Dieminger L (1978) A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 34:29–40

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Hammer CH, Abramovitz AS, Mayer MM (1976) A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components. J Immunol 117:830–834

    CAS  PubMed  Google Scholar 

  47. Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci U S A 74:2701–2705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Law SK, Lichtenberg NA, Levine RP (1979) Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123:1388–1394

    CAS  PubMed  Google Scholar 

  49. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A 77:5764–5768

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sim RB, Twose TM, Paterson DS, Sim E (1981) The covalent-binding reaction of complement component C3. Biochem J 193:115–127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. P1 G, Milder FJ, Janssen BJ (2008) Complement driven by conformational changes. Nat Rev Immunol 8:48–58

  52. Medicus RG, Götze O, Müller-Eberhard HJ (1976) Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med 144:1076–1093

    Article  CAS  PubMed  Google Scholar 

  53. Fearon DT, Austen KF (1975) Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A 72:3220–3224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Farries TC, Lachmann PJ, Harrison RA (1988) Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem J 252:47–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184–189

    CAS  PubMed  Google Scholar 

  56. Okada H, Tanaka H, Okada N (1983) Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur J Immunol 13:340–344

    Article  CAS  PubMed  Google Scholar 

  57. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1983) Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 80:5430–5434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558–1578

    Article  CAS  PubMed  Google Scholar 

  59. Medof ME, Kinoshita T, Silber R, Nussenzweig V (1985) Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A 82:2980–2984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A 76:5867–5871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Medicus RG, Melamed J, Arnaout MA (1983) Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immunol 13:465–470

    Article  CAS  PubMed  Google Scholar 

  62. Daha MR, Kok DJ, Van Es LA (1982) Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor. Clin Exp Immunol 50:209–214

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Fries LF, Prince GM, Gaither TA, Frank MM (1985) Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues. J Immunol 135:2673–2679

    CAS  PubMed  Google Scholar 

  64. Roberts WN, Wilson JG, Wong W, Jenkins DE Jr, Fearon DT, Austen KF, Nicholson-Weller A (1985) Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. J Immunol 134:512–517

    CAS  PubMed  Google Scholar 

  65. Seya T, Turner JR, Atkinson JP (1986) Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 163:837–855

    Article  CAS  PubMed  Google Scholar 

  66. Seya T1, Atkinson JP (1989) Functional properties of membrane cofactor protein of complement. Biochem J 264:581–588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Kojima A1, Iwata K, Seya T, Matsumoto M, Ariga H, Atkinson JP, Nagasawa S (1993) Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 151:1519–1527

    CAS  PubMed  Google Scholar 

  68. T1 S, Okada M, Matsumoto M, Hong KS, Kinoshita T, Atkinson JP (1991) Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol Immunol 28:1137–1147

  69. Fearon DT, Austen KF (1977) Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med 146:22–33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Fearon DT (1978) Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A 75:1971–1975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Tomlinson S, Pontes de Carvalho L, Vandekerckhove F, Nussenzweig V (1992) Resialylation of sialidase-treated sheep and human erythrocytes by Trypanosoma cruzi trans-sialidase: restoration of complement resistance of desialylated sheep erythrocytes. Glycobiology 2:549–551

    Article  CAS  PubMed  Google Scholar 

  72. Nydegger UE, Fearon DT, Austen KF (1978) Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proc Natl Acad Sci U S A 75:6078–6082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kazatchkine MD, Fearon DT, Austen KF (1979) Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 122:75–81

    CAS  PubMed  Google Scholar 

  74. Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A (1982) Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol 128:1278–1283

    CAS  PubMed  Google Scholar 

  75. Okada N, Yasuda T, Tsumita T, Okada H (1983) Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine. Immunology 48:129–140

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Pangburn MK, Morrison DC, Schreiber RD, Müller-Eberhard HJ (1980) Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol 124:977–982

    CAS  PubMed  Google Scholar 

  77. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1983) C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol 131:1930–1935

    CAS  PubMed  Google Scholar 

  78. Fries LF, Gaither TA, Hammer CH, Frank MM (1984) C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 160:1640–1655

    Article  CAS  PubMed  Google Scholar 

  79. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF (1979) Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 150:1202–1215

    Article  CAS  PubMed  Google Scholar 

  80. Meri S, Pangburn MK (1990) Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A 87:3982–3986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK (2006) Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 177:6308–6316

    Article  CAS  PubMed  Google Scholar 

  82. Meri S, Pangburn MK (1994) Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 198:52–59

    Article  CAS  PubMed  Google Scholar 

  83. Blaum BS (2017) The lectin self of complement factor H. Curr Opin Struct Biol 44:111–118. https://doi.org/10.1016/j.sbi.2017.01.005

    Article  CAS  PubMed  Google Scholar 

  84. Sharma AK, Pangburn MK (1996) Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A 93:10996–11001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM, Gordon DL (1998) Identification of the second heparin-binding domain in human complement factor H. J Immunol 160:3342–3348

    CAS  PubMed  Google Scholar 

  86. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S (2000) Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 275:27657–27662

    CAS  PubMed  Google Scholar 

  87. Giannakis E, Male DA, Ormsby RJ, Mold C, Jokiranta TS, Ranganathan S, Gordon DL (2001) Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol 1:433–443

    Article  CAS  PubMed  Google Scholar 

  88. Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN (2008) Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol 151:14–24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Kajander T, Lehtinen MJ, Hyvärinen S, Bhattacharjee A, Leung E, Isenman DE, Meri S, Goldman A, Jokiranta TS (2011) Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A 108:2897–2902. https://doi.org/10.1073/pnas.1017087108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. de Córdoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151:1–13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrín D, Stehle T (2015) Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol 11:77–82. https://doi.org/10.1038/nchembio.1696.

    Article  CAS  PubMed  Google Scholar 

  92. Schreiber RD, Müller-Eberhard HJ (1978) Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med 148:1722–1727

    Article  CAS  PubMed  Google Scholar 

  93. Kimura Y, Miwa T, Zhou L, Song WC (2008) Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111:732–740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Rawal N, Pangburn MK (1998) C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem 273:16828–16835

    Article  CAS  PubMed  Google Scholar 

  95. Coulthard LG, Woodruff TM (2015) Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 194(8):3542. https://doi.org/10.4049/jimmunol.1403068

    Article  CAS  PubMed  Google Scholar 

  96. Jing H, Macon KJ, Moore D, DeLucas LJ, Volanakis JE, Narayana SV (1999) Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D. EMBO J 18:804–814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P (2017) Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol 24:643–651. https://doi.org/10.1038/nsmb.3427

    Article  CAS  PubMed  Google Scholar 

  98. Daha MR, Fearon DT, Austen KF (1976) Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B. Immunology 31:789–796

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Milder FJ, Gomes L, Schouten A, Janssen BJ, Huizinga EG, Romijn RA, Hemrika W, Roos A, Daha MR, Gros P (2007) Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol 14:224–228

    Article  CAS  PubMed  Google Scholar 

  100. Pechtl IC, Neely RK, Dryden DT, Jones AC, Barlow PN (2011) Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus). Protein Sci 20(12):2102. https://doi.org/10.1002/pro.738

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Berends ET, Gorham RD Jr, Ruyken M, Soppe JA, Orhan H, Aerts PC, de Haas CJ, Gros P, Rooijakkers SH (2015) Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. BMC Biol 13:93. doi: https://doi.org/10.1186/s12915-015-0203-8.

  102. Pangburn MK, Müller-Eberhard HJ (1980) Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1114

    Article  CAS  PubMed  Google Scholar 

  103. Isenman DE, Kells DI, Cooper NR, Müller-Eberhard HJ, Pangburn MK (1981) Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20:4458–4467

    Article  CAS  PubMed  Google Scholar 

  104. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154:856–867

    Article  CAS  PubMed  Google Scholar 

  105. Pryzdial EL, Isenman DE (1988) A thermodynamic study of the interaction between human complement components C3b or C3(H2O) and factor B in solution. J Biol Chem 263:1733–1738

    CAS  PubMed  Google Scholar 

  106. Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370–2379

    Article  CAS  PubMed  Google Scholar 

  107. Nilsson B, Nilsson Ekdahl K (2012) The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217:1106–1110. https://doi.org/10.1016/j.imbio.2012.07.008

    Article  CAS  PubMed  Google Scholar 

  108. Carpenter CB, Ruddy S, Shehadeh IH, Müller-Eberhard HJ, Merrill JP, Austen KF (1969) Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE). J Clin Invest 48:1495–1505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Sissons JG, Liebowitch J, Amos N, Peters DK (1977) Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J Clin Invest 59:704–715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Farries TC, Finch JT, Lachmann PJ, Harrison RA (1987) Resolution and analysis of “native” and “activated” properdin. Biochem J 243:507–517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Pangburn MK (1989) Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol 142:202–207

    CAS  PubMed  Google Scholar 

  112. Higgins JM, Wiedemann H, Timpl R, Reid KB (1995) Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. J Immunol 155:5777–5785

    CAS  PubMed  Google Scholar 

  113. Pedersen D1, Roumenina L, Jensen RK, Gadeberg TA, Marinozzi C, Picard C, Rybkine T2, Thiel S, Sørensen UB, Stover C, Fremeaux-Bacchi V, Andersen GR (2017) Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO J 36:1084–1099. 10.15252/embj.201696173

    Article  CAS  PubMed  Google Scholar 

  114. Yang Y, Liu F, Franc V, Halim LA, Schellekens H, Heck AJ (2016) Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Nat Commun 7:13397. https://doi.org/10.1038/ncomms13397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Medicus RG, Esser AF, Fernandez HN, Müller-Eberhard HJ (1980) Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences. J Immunol 124:602–606

    CAS  PubMed  Google Scholar 

  116. Lutz HU, Fumia S, Schurtenberger C, Alaia V (2007) Opinion paper: stimulation of complement amplification or activation of the alternative pathway of complement? Mol Immunol 44:3862–3865

    Article  CAS  PubMed  Google Scholar 

  117. Junker A, Baatrup G, Svehag SE, Wang P, Holmström E, Sturfelt G, Sjöholm AG (1998) Binding of properdin to solid-phase immune complexes: critical role of the classical activation pathway of complement. Scand J Immunol 47:481–486

    Article  CAS  PubMed  Google Scholar 

  118. Vuagnat BB, Mach J, Le Doussal JM (2000) Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin. Mol Immunol 37:467–478

    Article  CAS  PubMed  Google Scholar 

  119. Hourcade DE (2006) The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem 281:2128–2132

    Article  CAS  PubMed  Google Scholar 

  120. Agarwal S, Specht CA, Haibin H, Ostroff GR, Ram S, Rice PA, Levitz SM (2011) Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio. 2. pii: e00178–11. doi: https://doi.org/10.1128/mBio.00178-11.

  121. Cortes C, Ferreira VP, Pangburn MK (2011) Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun 79:724–731. https://doi.org/10.1128/IAI.00980-10

    Article  CAS  PubMed  Google Scholar 

  122. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE (2007) Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 179:2600–2608

    Article  CAS  PubMed  Google Scholar 

  123. Xu W, Berger SP, Trouw LA, de Boer HC, Schlagwein N, Mutsaers C, Daha MR, van Kooten C (2008) Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol 180:7613–7621

    Article  CAS  PubMed  Google Scholar 

  124. Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 28:131–155. https://doi.org/10.1146/annurev-immunol-030409-101250

    Article  CAS  PubMed  Google Scholar 

  125. Harboe M, Garred P, Lindstad JK, Pharo A, Müller F, Stahl GL, Lambris JD, Mollnes TE (2012) The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol 189:2606–2613. https://doi.org/10.4049/jimmunol.1200269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Harboe M, Johnson C, Nymo S, Ekholt K, Schjalm C, Lindstad JK, Pharo A, Hellerud BC, Nilsson Ekdahl K, Mollnes TE, Nilsson PH (2017) Properdin binding to complement activating surfaces depends on initial C3b deposition. Proc Natl Acad Sci U S A 114:E534–E539. https://doi.org/10.1073/pnas.1612385114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Takahashi M, Ishida Y, Iwaki D, Kanno K, Suzuki T, Endo Y, Homma Y, Fujita T (2010) Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J Exp Med 207:29–37. https://doi.org/10.1084/jem.20090633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Banda NK, Takahashi M, Takahashi K, Stahl GL, Hyatt S, Glogowska M, Wiles TA, Endo Y, Fujita T, Holers VM, Arend WP (2011) Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol Immunol 49:281–289. https://doi.org/10.1016/j.molimm.2011.08.021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Ruseva MM, Takahashi M, Fujita T, Pickering MC (2014) C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. Clin Exp Immunol 176:84–92. https://doi.org/10.1111/cei.12244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Dobó J, Szakács D, Oroszlán G, Kortvely E, Kiss B, Boros E, Szász R, Závodszky P, Gál P, Pál G (2016) MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep 6:31877. https://doi.org/10.1038/srep31877

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Degn SE, Jensen L, Hansen AG, Duman D, Tekin M, Jensenius JC, Thiel S (2012) Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 189:3957–3969. https://doi.org/10.4049/jimmunol.1201736

    Article  CAS  PubMed  Google Scholar 

  132. Pihl R, Jensen L, Hansen AG, Thøgersen IB, Andres S, Dagnæs-Hansen F, Oexle K, Enghild JJ, Thiel S (2017) Analysis of factor D isoforms in Malpuech-Michels-Mingarelli-Carnevale patients highlights the role of MASP-3 as a maturase in the alternative pathway of complement. J Immunol. pii: ji1700518. doi: https://doi.org/10.4049/jimmunol.1700518.

  133. Pascual M, Steiger G, Estreicher J, Macon K, Volanakis JE, Schifferli JA (1988) Metabolism of complement factor D in renal failure. Kidney Int 34:529–536

    Article  CAS  PubMed  Google Scholar 

  134. Wu X, Hutson I, Hourcade D, Harris C, Atkinson JP (2016) Regulation of the mouse adipose factor D biosynthesis by the endocrine hypothalamic-pituatory-adrenal axis. Immunobiology 221:1171

    Article  Google Scholar 

  135. Misasi R, Huemer HP, Schwaeble W, Sölder E, Larcher C, Dierich MP (1989) Human complement factor H: an additional gene product of 43 kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complement. Eur J Immunol 19:1765–1768

    Article  CAS  PubMed  Google Scholar 

  136. Estaller C, Schwaeble W, Dierich M, Weiss EH (1991) Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur J Immunol 21:799–802

    Article  CAS  PubMed  Google Scholar 

  137. Friese MA, Hellwage J, Jokiranta TS, Meri S, Müller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF (2000) Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 121:406–415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN (2014) Identification of factor H-liken 1 as the predominant complement regulator in Bruch’s membrane: implications for age-related macular degeneration. J Immunol 193:4962–4970. https://doi.org/10.4049/jimmunol.1401613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Estaller C, Koistinen V, Schwaeble W, Dierich MP, Weiss EH (1991) Cloning of the 1.4-kb mRNA species of human complement factor H reveals a novel member of the short consensus repeat family related to the carboxy terminal of the classical 150-kDa molecule. J Immunol 146:3190–3196

    CAS  PubMed  Google Scholar 

  140. Timmann C, Leippe M, Horstmann RD (1991) Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J Immunol 146:1265–1270

    CAS  PubMed  Google Scholar 

  141. Zipfel PF, Skerka C (1994) Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today 15:121–126

    Article  CAS  PubMed  Google Scholar 

  142. Fijen CA, Kuijper EJ, Te Bulte M, van de Heuvel MM, Holdrinet AC, Sim RB, Daha MR, Dankert J (1996) Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol 105:511–516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Heinen S, Hartmann A, Lauer N, Wiehl U, Dahse HM, Schirmer S, Gropp K, Enghardt T, Wallich R, Hälbich S, Mihlan M, Schlötzer-Schrehardt U, Zipfel PF, Skerka C (2009) Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114:2439–2447. https://doi.org/10.1182/blood-2009-02-205641

    Article  CAS  PubMed  Google Scholar 

  144. Eberhardt HU, Buhlmann D, Hortschansky P, Chen Q, Böhm S, Kemper MJ, Wallich R, Hartmann A, Hallström T, Zipfel PF, Skerka C (2013) Human factor H-related protein 2 (CFHR2) regulates complement activation. PLoS One 8:e78617. https://doi.org/10.1371/journal.pone.0078617

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM (2013) Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A 110:4685–4690. https://doi.org/10.1073/pnas.1219260110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Józsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodríguez de Córdoba S (2015) Factor H-related proteins determine complement-activating surfaces. Trends Immunol 36:374–384. https://doi.org/10.1016/j.it.2015.04.008

    Article  PubMed  CAS  Google Scholar 

  147. Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M (2015) A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol 26:209–219. https://doi.org/10.1681/ASN.2013121339

    Article  CAS  PubMed  Google Scholar 

  148. Medjeral-Thomas N, Pickering MC (2016) The complement factor H-related proteins. Immunol Rev 274:191–201. https://doi.org/10.1111/imr.12477

    Article  CAS  PubMed  Google Scholar 

  149. Holers VM (2008) The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223:300–316. https://doi.org/10.1111/j.1600-065X.2008.00641.x

    Article  CAS  PubMed  Google Scholar 

  150. Maibaum J, Liao SM, Vulpetti A, Ostermann N, Randl S, Rüdisser S, Lorthiois E, Erbel P, Kinzel B, Kolb FA, Barbieri S, Wagner J, Durand C, Fettis K, Dussauge S, Hughes N, Delgado O, Hommel U, Gould T, Mac Sweeney A, Gerhartz B, Cumin F, Flohr S, Schubart A, Jaffee B, Harrison R, Risitano AM, Eder J, Anderson K (2016) Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol 12:1105–1110. https://doi.org/10.1038/nchembio.2208

    Article  CAS  PubMed  Google Scholar 

  151. Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA (2017) Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 102:466–475. https://doi.org/10.3324/haematol.2016.153312

    Article  PubMed  PubMed Central  Google Scholar 

  152. DiScipio RG (1982) The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45:587–595

    CAS  PubMed  PubMed Central  Google Scholar 

  153. Day NK, Schreiber RD, Götze O, Müller-Eberhard HJ (1976) Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule. Scand J Immunol 5:715–720

    Article  CAS  PubMed  Google Scholar 

  154. Nydegger UE, Fearon DT, Austen KF (1978) The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol 120:1404–1408

    CAS  PubMed  Google Scholar 

  155. Forristal J, Iitaka K, Vallota EH, West CD (1977) Correlations between serum factor B and C3b inactivator levels in normal subjects and in patients with infections, nephrosis and hypocomplementaemic glomerulonephritis. Clin Exp Immunol 28:61–71

    CAS  PubMed  PubMed Central  Google Scholar 

  156. Esparza-Gordillo J, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, Rodríguez de Córdoba S (2004) Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 56:77–82

    Article  CAS  PubMed  Google Scholar 

  157. Heurich M, Martínez-Barricarte R, Francis NJ, Roberts DL, Rodríguez de Córdoba S, Morgan BP, Harris CL (2011) Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 108:8761–8766. https://doi.org/10.1073/pnas.1019338108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Fearon DT (1979) Activation of the alternative complement pathway. CRC Crit Rev Immunol 1:1–32

    CAS  PubMed  Google Scholar 

  159. Pangburn MK, Müller-Eberhard HJ (1984) The alternative pathway of complement. Springer Semin Immunopathol 7:163–192

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to acknowledge, with gratitude, the contributions that Professor Peter Lachmann and the late Professor Fred Rosen have made to his understanding and thinking about the complement system.

Author information

Authors and Affiliations

  1. Institute of Infection and Immunity, School of Medicine, Cardiff University, Henry Wellcome Building, Heath Park, Cardiff, CF14 4XN, UK

    Richard A. Harrison

Authors
  1. Richard A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard A. Harrison.

Additional information

This article is a contribution to the special issue on Complement in Health and Disease: Novel Aspects and Insights - Guest Editors: Paul Morgan and David Kavanagh

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrison, R.A. The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation?. Semin Immunopathol 40, 15–35 (2018). https://doi.org/10.1007/s00281-017-0661-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-017-0661-x

Keywords

search

Navigation